Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.
Conclusions: PSMA-CAR-T cells co-expressing ICR can be envisaged as a new therapeutic strategy for prostate cancer and support the translation of this enhanced approach in the clinical setting.
PMID: 32208880 [PubMed - as supplied by publisher]
Source: Cancer Biology and Therapy - Category: Cancer & Oncology Authors: Weimin S, Abula A, Qianghong D, Wenguang W Tags: Cancer Biol Ther Source Type: research